Last update July 11, 2016
Very Low Risk
We do not have alternatives for リンコマイシン since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
リンコマイシン is Lincomycin in Japanese.Is written in other languages:
リンコマイシン is also known as
リンコマイシン belongs to this group or family:
Main tradenames from several countries containing リンコマイシン in its composition:
|Oral Bioavail.||20 - 35||%|
|Tmax||2 - 4||hours|
|M/P ratio||0.2 - 0.9||-|
|Relative Dose||0. 6 - 0. 8||%|
|Ped.Relat.Dose||1 - 2||%|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A Lincosamide type antibacterial drug which is structurally similar to clindamycin.
As clindamycin, it is excreted in breast milk in clinically non-significant amount with no problems being reported in infants whose mothers were treated with it.
Its low oral bioavailability that further decreases with simultaneous ingestion of food, hinders the drug passage to the infant plasma from ingested mother’s milk , except in preterm babies and immediate neonatal period, in which they may occur an increased intestinal permeability.
Among infants whose mothers are treated with antibiotics, an alteration of the intestinal flora may appear. In case of infant's fever, the possibility of false negative results of bacterial cultures should be taken into account.